AR106951A1 - CANNABINOIDS AS ANTIOXIDANTS AND NEUROPROTECTORS - Google Patents
CANNABINOIDS AS ANTIOXIDANTS AND NEUROPROTECTORSInfo
- Publication number
- AR106951A1 AR106951A1 ARP160103722A ARP160103722A AR106951A1 AR 106951 A1 AR106951 A1 AR 106951A1 AR P160103722 A ARP160103722 A AR P160103722A AR P160103722 A ARP160103722 A AR P160103722A AR 106951 A1 AR106951 A1 AR 106951A1
- Authority
- AR
- Argentina
- Prior art keywords
- cannabinoids
- antioxidants
- cannabinoid
- subject
- neuroprotectors
- Prior art date
Links
- 229930003827 cannabinoid Natural products 0.000 title abstract 5
- 239000003557 cannabinoid Substances 0.000 title abstract 5
- 229940065144 cannabinoids Drugs 0.000 title abstract 3
- 239000003963 antioxidant agent Substances 0.000 title abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 abstract 1
- 229960003453 cannabinol Drugs 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 208000023589 ischemic disease Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Utilización de cannabinoides como antioxidantes y neuroprotectotres. Para limitar el daño neurológico posterior a isquemias, tales como apoplejia y trauma, o en el tratamiento de enfermedades neuro degenerativas. Cannabinoides no psicoactivos como el cannabinol son particularmente ventajosos para utilizar. Reivindicación 15: Un método de tratamiento de una enfermedad isquémica o neurodegenerativa en el sistema nervioso central de un sujeto, que comprende administrar al sujeto una cantidad terapéuticamente eficaz de un cannabinoide, en el que el cannabinoide es: un compuesto de fórmula (1) donde R es H, alquilo sustituido o no sustituido, carboxilo, alcoxi, arilo, ariloxi, arilalquilo, halo o amino.Use of cannabinoids as antioxidants and neuroprotectotres. To limit the neurological damage after ischemia, such as stroke and trauma, or in the treatment of neuro degenerative diseases. Non-psychoactive cannabinoids such as cannabinol are particularly advantageous to use. Claim 15: A method of treating an ischemic or neurodegenerative disease in the central nervous system of a subject, comprising administering to the subject a therapeutically effective amount of a cannabinoid, wherein the cannabinoid is: a compound of formula (1) wherein R is H, substituted or unsubstituted alkyl, carboxyl, alkoxy, aryl, aryloxy, arylalkyl, halo or amino.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP160103722A AR106951A1 (en) | 2016-12-02 | 2016-12-02 | CANNABINOIDS AS ANTIOXIDANTS AND NEUROPROTECTORS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP160103722A AR106951A1 (en) | 2016-12-02 | 2016-12-02 | CANNABINOIDS AS ANTIOXIDANTS AND NEUROPROTECTORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106951A1 true AR106951A1 (en) | 2018-03-07 |
Family
ID=61768565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103722A AR106951A1 (en) | 2016-12-02 | 2016-12-02 | CANNABINOIDS AS ANTIOXIDANTS AND NEUROPROTECTORS |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR106951A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210403408A1 (en) * | 2018-10-31 | 2021-12-30 | Baymedica, Inc. | Cannabinoid analogs and methods for their preparation |
-
2016
- 2016-12-02 AR ARP160103722A patent/AR106951A1/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210403408A1 (en) * | 2018-10-31 | 2021-12-30 | Baymedica, Inc. | Cannabinoid analogs and methods for their preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20069418A (en) | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | |
| CL2019002167A1 (en) | Compound of formula (ic) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising said compound or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, and its use in the treatment of familial dysautonomia by improving the marn joint. (divisional application 201701823.) | |
| CL2019001079A1 (en) | Methods for using indazole-3-carboxamides and their use as inhibitors of the wnt / b-catenin signaling pathway. | |
| MX2020001757A (en) | COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES. | |
| PH12018500087A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
| MX373962B (en) | Aryl, heteroaryl and heterocyclic compounds for the treatment of complement-mediated disorders. | |
| MX2018007774A (en) | Heterocyclic compounds as immunomodulators. | |
| ECSP20042640A (en) | DERIVATIVES OF INDOL 1, 3, 4, 5-TETRAHIDRO-2H-PIRIDO [4,3-B] FOR THE TREATMENT, RELIEF, OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES, SUCH AS ALZHEIMER'S DISEASE | |
| CO6670589A2 (en) | Compounds to reduce the production of beta-amyloid | |
| MX2016014253A (en) | Inhibitors of lysine specific demethylase-1. | |
| PE20151542A1 (en) | TETRAHYDROPYRROTHIAZINE COMPOUNDS | |
| CR20180452A (en) | NICOTIC ACETILCOLINE RECEPTORS ALOSTERIC MODULATORS | |
| MX2024010721A (en) | Topical cyclosporine-containing formulations and uses thereof. | |
| BR112017005917A2 (en) | processes and compositions for inducing protective immunity against human immunodeficiency virus infection | |
| MX2016013151A (en) | Novel cannabidiol quinone derivatives. | |
| CO2019001181A2 (en) | Heteroarylcarboxamide compounds as ripk2 inhibitors | |
| MD4626B1 (en) | Tamoxifen derivatives for the treatment of neoplastic disorders, especially high HER2 protein | |
| MX2019009185A (en) | NOVEL HETEROCICLIC COMPOUND, ITS PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT. | |
| EP4553065A3 (en) | Novel compounds for treating mitochondrial disease | |
| MX2016007803A (en) | Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system. | |
| CO2017003321A2 (en) | Lysine gingipain inhibitors | |
| JOP20210127A1 (en) | Heterocyclic aromatic compounds as vanin inhibitors | |
| BR112016025396A2 (en) | heterocyclyl butanamide derivatives | |
| EA202091020A1 (en) | SUBSTITUTED IMIDAZOPYRIDINAMIDES AND THEIR APPLICATION | |
| MX385698B (en) | USE OF A COMPOUND COMPRISING A PYRROLIDINYL AND PYRIMIDINYL GROUP TO TREAT EYE DISEASES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |